We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Wave Life Sciences (WVE): Can Its 11.4% Jump Turn into More Strength?
Read MoreHide Full Article
Wave Life Sciences (WVE - Free Report) shares ended the last trading session 11.4% higher at $8.19. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.5% loss over the past four weeks.
Wave Life Sciences’ sudden stock price surge can be attributed to growing investor optimism around its expanding RNA-based therapeutics pipeline. The company’s proprietary PRISM platform enables breakthroughs across multiple RNA modalities, including editing, splicing, and silencing, targeting both rare and common diseases. Its clinical pipeline includes an obesity candidate, WVE-007, alongside other promising programs in alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease.
This biopharmaceutical company is expected to post quarterly loss of $0.30 per share in its upcoming report, which represents a year-over-year change of +36.2%. Revenues are expected to be $12.95 million, up 268.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Wave Life Sciences, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on WVE going forward to see if this recent jump can turn into more strength down the road.
Wave Life Sciences is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Lineage Cell (LCTX - Free Report) , finished the last trading session 1.2% higher at $1.75. LCTX has returned 43% over the past month.
For Lineage Cell, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.02. This represents no change from what the company reported a year ago. Lineage Cell currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Strength Seen in Wave Life Sciences (WVE): Can Its 11.4% Jump Turn into More Strength?
Wave Life Sciences (WVE - Free Report) shares ended the last trading session 11.4% higher at $8.19. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.5% loss over the past four weeks.
Wave Life Sciences’ sudden stock price surge can be attributed to growing investor optimism around its expanding RNA-based therapeutics pipeline. The company’s proprietary PRISM platform enables breakthroughs across multiple RNA modalities, including editing, splicing, and silencing, targeting both rare and common diseases. Its clinical pipeline includes an obesity candidate, WVE-007, alongside other promising programs in alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease.
This biopharmaceutical company is expected to post quarterly loss of $0.30 per share in its upcoming report, which represents a year-over-year change of +36.2%. Revenues are expected to be $12.95 million, up 268.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Wave Life Sciences, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on WVE going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Wave Life Sciences is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Lineage Cell (LCTX - Free Report) , finished the last trading session 1.2% higher at $1.75. LCTX has returned 43% over the past month.
For Lineage Cell, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.02. This represents no change from what the company reported a year ago. Lineage Cell currently has a Zacks Rank of #3 (Hold).